View Financial HealthNirvana Life Sciences 配当と自社株買い配当金 基準チェック /06Nirvana Life Sciences配当金を支払った記録がありません。主要情報n/a配当利回り-414.4%バイバック利回り総株主利回り-414.4%将来の配当利回りn/a配当成長n/a次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向n/a最近の配当と自社株買いの更新更新なしすべての更新を表示Recent updatesBoard Change • Apr 20Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 2 highly experienced directors. 1 independent director (2 non-independent directors). Independent Director Mark Marissen was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Board Change • Feb 25Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 2 highly experienced directors. 1 independent director (2 non-independent directors). Independent Director Mark Marissen was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Board Change • Jan 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 2 highly experienced directors. 1 independent director (2 non-independent directors). Independent Director Mark Marissen was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Board Change • Dec 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 2 highly experienced directors. 1 independent director (2 non-independent directors). Independent Director Mark Marissen was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Board Change • Nov 03Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 1 highly experienced director. 1 independent director (2 non-independent directors). Independent Director Mark Marissen was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Board Change • Oct 10Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 1 highly experienced director. 1 independent director (2 non-independent directors). Independent Director Mark Marissen was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Board Change • Sep 23Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 1 highly experienced director. 1 independent director (2 non-independent directors). Independent Director Mark Marissen was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Board Change • Sep 02Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 1 highly experienced director. 1 independent director (2 non-independent directors). Independent Director Mark Marissen was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Board Change • Jul 22Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 1 highly experienced director. 1 independent director (2 non-independent directors). Independent Director Mark Marissen was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Board Change • Jul 04Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 1 highly experienced director. 1 independent director (2 non-independent directors). Independent Director Mark Marissen was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Board Change • Jun 19Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 1 highly experienced director. 1 independent director (2 non-independent directors). Independent Director Mark Marissen was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Board Change • May 05Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 1 highly experienced director. 1 independent director (2 non-independent directors). Independent Director Mark Marissen was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Board Change • Apr 15Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 1 highly experienced director. 1 independent director (2 non-independent directors). Independent Director Mark Marissen was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Board Change • Mar 21Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Director Mark Marissen was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Mar 07Nirvana Life Sciences Inc., Annual General Meeting, Apr 30, 2025Nirvana Life Sciences Inc., Annual General Meeting, Apr 30, 2025. Location: british columbia, vancouver CanadaBoard Change • Feb 28Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Director Mark Marissen was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • Feb 10Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Director Mark Marissen was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • Jan 08Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Director Mark Marissen was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.New Risk • Nov 03New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -CA$314k This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$314k free cash flow). Negative equity (-CA$753k). Revenue is less than US$1m. Market cap is less than US$10m (CA$1.45m market cap, or US$1.05m). Minor Risk Shareholders have been diluted in the past year (42% increase in shares outstanding).New Risk • Oct 21New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended January 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Negative equity (-CA$548k). Revenue is less than US$1m. Market cap is less than US$10m (CA$4.82m market cap, or US$3.52m). Minor Risks Latest financial reports are more than 6 months old (reported January 2023 fiscal period end). Shareholders have been diluted in the past year (42% increase in shares outstanding).お知らせ • Oct 19Nirvana Life Sciences Inc., Annual General Meeting, Dec 18, 2023Nirvana Life Sciences Inc., Annual General Meeting, Dec 18, 2023.お知らせ • Jun 08Nirvana Life Sciences Inc. (CNSX:NIRV) has entered into a definitive agreement to acquire Medsmart Dispensary Inc. for $0.13 million.Nirvana Life Sciences Inc. (CNSX:NIRV) has entered into a definitive agreement to acquire Medsmart Dispensary Inc. for $0.13 million on June 7, 2023. Nirvana Life Sciences Inc. acquired Medsmart in exchange for 5 million shares of Nirvana valued at $0.10 per share.お知らせ • May 11Nirvana Life Sciences Inc. announced a financing transactionNirvana Life Sciences Inc. announced a CAD 0.05 unit private placement on May 10, 2023. Each unit consisting of one common share and one half common share purchase warrant, each full warrant exercisable for an additional common share for aggregate gross proceeds of CAD 320,000. The company will now issue 6,400,000 common shares and 3,200,000 common share purchase warrants, each warrant being exercisable at CAD 0.15 per common share for a period of 24 months from date of issuance. On the same date, The company received investment in its first tranche closing.Board Change • Jan 03No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 6 non-independent directors. Member of Advisory Board Andrew Samann was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • Nov 16No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 6 non-independent directors. Member of Advisory Board Andrew Samann was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Nov 10Nirvana Life Sciences Inc. Appoints Sheldon Inwentash to the Company's Board of DirectorsNirvana Life Sciences Inc. announce the appointment of Mr. Sheldon Inwentash to the Company's Board of Directors. Mr. Inwentash is founder, chairman and chief executive officer of ThreeD Capital Inc. A veteran entrepreneur, Sheldon has more than 30 years of successful investing experience and an extensive track record of achieving significant ROI for his investors and profitability for the companies in which he invests. He founded ThreeD Capital to provide unique investment opportunities in several areas, specifically early stages of small cap stock, resource and disruptive technologies. Sheldon graduated from the University of Toronto with a B.Comm degree and, later, was awarded an honorary Doctor of Law degree from the university for his leadership as an entrepreneur, philanthropist and for his dedication to youth.お知らせ • Sep 08Nirvana Life Sciences Inc. Announces Method for Producing MDMA That Reduces Manufacturing Time by Two ThirdsNirvana Life Sciences Inc. report the development of a more efficient method for producing MDMA. Nirvana Life Sciences Inc. announced the development of a novel method of producing MDMA (3,4-methylenedioxy methamphetamine) that greatly reduces manufacturing time. This 3-step synthesis, starting from the precursor safrole, takes as little as 24 hours to complete, depending upon which method of reduction of the ketone to the secondary amine is being used. This is approximately one third of the time that's required to complete current production methods using iso-safrole as an intermediate. Nirvana has filed an Application with the US Patent Office for this invention. MDMA was first synthesized in 1912, but it was not researched for its therapeutic potential until just recently. The drug is a potent central nervous system (CNS) stimulant the varies greatly in effect from other common stimulants found in the same phenethylamine family of compounds. It is currently being studied and used for the treatment of a wide range of psychiatric disorders such as Post Traumatic Stress Disorder (PTSD), depression and anxiety to name a few. MDMA assisted psychotherapy is currently in phase three clinical trials for the treatment of PTSD in the US, Canada, and Israel. This year the FDA expanded access to MDMA, allowing for its compassionate use in clinical settings by patients who have had no success with other FDA approved treatment options. MDMA effectively shuts down the brain's fight-or-flight response and creates a sense of empathy in patients, allowing them to process trauma more effectively. The drug increases the amount of serotonin in the synaptic clefts of serotonergic neurons. It also binds to various serotonin receptors and activates them in excess, while simultaneously reducing the reuptake of other neurotransmitters, which is the drugs primary mechanism of action Lead chemist and Head of Innovation for Nirvana Life Sciences Inc., Robert August, was one of the first researchers to successfully crystallize MDMA HCl Monohydrate, a novel form of MDMA with increased bioavailability and efficacy. The method of synthesis that he developed can also be seamlessly integrated into the production of MDMA HCl Monohydrate, of which Nirvana Life Sciences Inc. recently announced a patent pending for. With the growing surge in interest in the research of MDMA in the past few years, and the increasing potentials of its use in therapeutic settings, Nirvana believes that this breakthrough is a significant advance in the emerging psychedelic medicines space.お知らせ • Aug 09Nirvana Life Sciences Inc. Announces Executive ChangesNirvana Life Sciences Inc. announced that Connie Hang has resigned as Chief Financial Officer of the Company. She will continue serving the Company as a Contractor. Annie Storey, CPA, CA, BBA has been appointed as Chief Financial Officer, effective immediately. Ms. Storey, a director of the Company since 2017, brings over 25 years' experience in accounting, auditing, financial reporting and corporate services for Canadian and US public companies in the mining, entertainment and biotechnology sectors. Ms Storey has a keen interest in the development new approaches to manage addictions and currently serves as a director of the advocacy group Moms Stop the Harm.お知らせ • Jun 24Nirvana Life Sciences Announces Filing of Patent for Novel Isolation of 4-PO-Psilocin Prodrug CompoundNirvana Life Sciences Inc. reported that it has filed a provisional patent application for a novel process for the isolation of a psychedelic 4-PO-Psilocin compound. The process, developed by Nirvana's Head of Innovation, Robert August allows for the isolation of 4- PO-Psilocin, a substituted tryptamine and psychoactive prodrug that is produced alongside psilocybin and psilocin. Its pharmacological effects are virtually identical to those produced by psilocybin since both are prodrugs. Both are metabolized in the human body to produce the psychoactive compound psilocin, which is responsible for the majority of psychoactive effects. The 4-PO-Psilocin can be purified by crystallization to an API. It can also be converted to a biologically active and water-soluble salt to yield a final compound 4-PO-Psilocin with a purity greater than 99%. The ability to convert the 4-PO-Psilocin compound into a water-soluble salt will change the current landscape of delivery systems in the psychedelic sector. The high rate of bioavailability will lower the required volume of psychedelic compound to achieve the same result. This will substantially increase the efficacy and safety in administering psychedelic compounds in clinical settings.お知らせ • Jun 11Nirvana Life Sciences Announces Patent FilingNirvana Life Sciences Inc. report that it has filed a new provisional patent application with the United States Patent and Trademark Office entitled Method of Psilocybin Extraction and Method of use of Psilocybin in modulating Heroin and Memory Retrieval (the "Patent Application"). The Patent Application contains new inventive claims for extraction as well as inventive methods for use of Psilocybin to affect relapse and further demonstrates the progress that the Company is making toward developing products that can have a meaningful impact on opioid addiction.お知らせ • Jun 04Nirvana Life Sciences Inc. Announces Positive Results for Addiction Relapse Prevention from Their Latest Pre-Clinical Psychedelic Drug StudyNirvana Life Sciences Inc. in conjunction with Integrative Therapy Discovery Labs in Italy, have released comprehensive data on a scientific study that aims in determining the effects that psilocybin has on the heroin addicted brain. The study was carried out by Dr. Massimo Nabissi, from the School of Pharmacy Section of Experimental Medicine, University of Camerino in Camerino, Italy. The preclinical study evaluated the effect of psilocybin on in-vitro rat brain cell line models and an in-vivo rat model on heroin self-administration and reinstatement of heroin seeking behavior following memory retrieval tests. Drug self-administration is regarded as a gold-standard preclinical model of addiction and substance-use disorders. The aim of the project was threefold and are as follows. To evaluate the effect of psilocybin in modulating heroin molecular pathways in vitro rat brain cell line models. To evaluate the effect of psilocybin on heroin self-administration. To evaluate the effect of psilocybin on reinstatement of heroin seeking following memory retrieval test. Gene Analysis was performed by the Clariom S Assay tool. This machine serves as a next generation transcriptome-wide gene-level expression profiling tool, which allows for the fastest, simplest, and most scalable path to generating actionable results. Based on industry-leading microarray technology, the novel rat Clariom S Assay provides extensive coverage of all known well-annotated genes, compatibility with clinical sample types, scalable formats, and flexible data analysis software. The GeneChip Rat Genome 230 2.0 Assay was used to evaluate gene expression levels and in cell lines that were treated with heroin and psilocybin and with psilocybin in combination with heroin. The immortalized rat hypothalamus cells were derived from the hypothalamus of a 4-month-old Fisher Rat. The hippocampal cells derived from the rats' hippocampi were treated daily with heroin and psilocybin, alone or in combination. After 48 hours, cell lines were collected for RNA extraction and gene array analysis. For each of the comparisons indicated, an electronic file was created that includes differentially expressed transcripts that were identified in both H19-7 and RCTH-1 cells with extended annotations. A second file was created that made comparisons evidencing only the transcript differences where the Ct value was highly different as a final analysis. For each of these data sets, only the genes whose expression was reverted by psilocybin and in the treatments consisting of heroin plus psilocybin were selected. Moreover, only the genes whose expression was psilocybin dose dependent were considered. In summary, the potential candidate genes whose expression in heroin treatment was reverted by psilocybin and evidenced in the electronic file reports were selected. The effect of heroin and psilocybin in reducing cell viability was evaluated in HT19-7 and RCHT-1 cell lines by daily administration. Cells were treated for 48 hours with either heroin or psilocybin or with a combination of heroin with psilocybin and then were analyzed. The percentage of cell viability was evaluated by a cell viability assay whose results showed a dose-dependent heroin effect in the RCHT-1 cell line with specific IC50 values. While in HT19-7 cell lines, no cytotoxic effects were observed at the concentrations used. Regarding psilocybin, similar results were obtained in cell lines with specific IC50 values and with both RCHT-1 and HT19-7 cell lines. To gain further insight, heroin was combined with psilocybin at varying doses to evaluate the optimal combination for transcriptional study. The results showed that when used together at varying dosages, the combinations were not cytotoxic in either of the two cell lines. The study goes on to show how treatment with psilocybin effected self-administered heroin use via lever presses along with the overall effect that psilocybin combined with heroin had on certain behavioral models in both male and female Wistar rat populations. A preliminary experiment aimed at testing the efficacy of psilocybin to prevent heroin relapse following cue memory reconsolidation was also conducted. Altogether, these results suggest that psilocybin decreased reinstatement of heroin seeking in female rats. As a final analysis, the gene data evidenced in the study was subjected to a comprehensive academic wide search of available current littérature and, although information regarding a correlation with psilocybin and opioid addiction was available, a transcriptome analysis for heroin and psilocybin and their co-combination has never been previously investigated. As a result, the data presented in this study can be extremely useful for determining a better understanding of dependent doses and the molecular mechanisms involved in the potential modulation of heroin (or opioids in general) addiction and dependence. In summary, the information contained within the study dealing with relapse prevention is new and groundbreaking evidence in the field of pharmaceutical addictions medicine and chemotherapy. This type of comprehensive study, which constitutes concrete scientific evidence-based data, is at the heart of Nirvana Life Sciences' business objective which is to develop and seek FDA approval for therapeutic formulations and novel pharmaceuticals.お知らせ • Jun 01Nirvana Life Sciences Inc. announced that it has received CAD 0.15 million in funding from ThreeD Capital Inc.Nirvana Life Sciences Inc. (CNSX:NIRV) announced a non-brokered private placement of 500,000 units at a price of CAD 0.30 per unit for gross proceeds of CAD 150,000 from returning investor ThreeD Capital Inc. on May 31, 2022. Each unit consists of one share and one warrant to purchase a share at a price of CAD 0.50 per share with an expiry date of May 29, 2025. The shares issued will be subject to a statutory four-month hold period.Board Change • Apr 27No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Member of Advisory Board Andrew Samann was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Apr 06Nirvana Life Sciences Inc. Announces the Appointment of Andrew Samann to Advisory BoardNirvana Life Sciences Inc. announced the appointment of Mr. Andrew Samann to the Company's Advisory Board. Andrew Samann is CEO and Principal Consultant of Orion GMP Solutions.決済の安定と成長配当データの取得安定した配当: NIRV.Xの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。増加する配当: NIRV.Xの配当金が増加しているかどうかを判断するにはデータが不十分です。配当利回り対市場Nirvana Life Sciences 配当利回り対市場NIRV.X 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (NIRV.X)n/a市場下位25% (CA)1.7%市場トップ25% (CA)5.4%業界平均 (Pharmaceuticals)2.2%アナリスト予想 (NIRV.X) (最長3年)n/a注目すべき配当: NIRV.Xは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。高配当: NIRV.Xは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。株主への利益配当収益カバレッジ: NIRV.Xの 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。株主配当金キャッシュフローカバレッジ: NIRV.Xが配当金を報告していないため、配当金の持続可能性を計算できません。高配当企業の発掘7D1Y7D1Y7D1YCA 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/07 08:25終値2026/04/23 00:00収益2026/01/31年間収益2025/04/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Nirvana Life Sciences Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
Board Change • Apr 20Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 2 highly experienced directors. 1 independent director (2 non-independent directors). Independent Director Mark Marissen was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Board Change • Feb 25Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 2 highly experienced directors. 1 independent director (2 non-independent directors). Independent Director Mark Marissen was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Board Change • Jan 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 2 highly experienced directors. 1 independent director (2 non-independent directors). Independent Director Mark Marissen was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Board Change • Dec 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 2 highly experienced directors. 1 independent director (2 non-independent directors). Independent Director Mark Marissen was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Board Change • Nov 03Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 1 highly experienced director. 1 independent director (2 non-independent directors). Independent Director Mark Marissen was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Board Change • Oct 10Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 1 highly experienced director. 1 independent director (2 non-independent directors). Independent Director Mark Marissen was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Board Change • Sep 23Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 1 highly experienced director. 1 independent director (2 non-independent directors). Independent Director Mark Marissen was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Board Change • Sep 02Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 1 highly experienced director. 1 independent director (2 non-independent directors). Independent Director Mark Marissen was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Board Change • Jul 22Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 1 highly experienced director. 1 independent director (2 non-independent directors). Independent Director Mark Marissen was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Board Change • Jul 04Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 1 highly experienced director. 1 independent director (2 non-independent directors). Independent Director Mark Marissen was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Board Change • Jun 19Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 1 highly experienced director. 1 independent director (2 non-independent directors). Independent Director Mark Marissen was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Board Change • May 05Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 1 highly experienced director. 1 independent director (2 non-independent directors). Independent Director Mark Marissen was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Board Change • Apr 15Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 1 highly experienced director. 1 independent director (2 non-independent directors). Independent Director Mark Marissen was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Board Change • Mar 21Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Director Mark Marissen was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Mar 07Nirvana Life Sciences Inc., Annual General Meeting, Apr 30, 2025Nirvana Life Sciences Inc., Annual General Meeting, Apr 30, 2025. Location: british columbia, vancouver Canada
Board Change • Feb 28Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Director Mark Marissen was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • Feb 10Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Director Mark Marissen was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • Jan 08Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Director Mark Marissen was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
New Risk • Nov 03New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -CA$314k This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$314k free cash flow). Negative equity (-CA$753k). Revenue is less than US$1m. Market cap is less than US$10m (CA$1.45m market cap, or US$1.05m). Minor Risk Shareholders have been diluted in the past year (42% increase in shares outstanding).
New Risk • Oct 21New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended January 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Negative equity (-CA$548k). Revenue is less than US$1m. Market cap is less than US$10m (CA$4.82m market cap, or US$3.52m). Minor Risks Latest financial reports are more than 6 months old (reported January 2023 fiscal period end). Shareholders have been diluted in the past year (42% increase in shares outstanding).
お知らせ • Oct 19Nirvana Life Sciences Inc., Annual General Meeting, Dec 18, 2023Nirvana Life Sciences Inc., Annual General Meeting, Dec 18, 2023.
お知らせ • Jun 08Nirvana Life Sciences Inc. (CNSX:NIRV) has entered into a definitive agreement to acquire Medsmart Dispensary Inc. for $0.13 million.Nirvana Life Sciences Inc. (CNSX:NIRV) has entered into a definitive agreement to acquire Medsmart Dispensary Inc. for $0.13 million on June 7, 2023. Nirvana Life Sciences Inc. acquired Medsmart in exchange for 5 million shares of Nirvana valued at $0.10 per share.
お知らせ • May 11Nirvana Life Sciences Inc. announced a financing transactionNirvana Life Sciences Inc. announced a CAD 0.05 unit private placement on May 10, 2023. Each unit consisting of one common share and one half common share purchase warrant, each full warrant exercisable for an additional common share for aggregate gross proceeds of CAD 320,000. The company will now issue 6,400,000 common shares and 3,200,000 common share purchase warrants, each warrant being exercisable at CAD 0.15 per common share for a period of 24 months from date of issuance. On the same date, The company received investment in its first tranche closing.
Board Change • Jan 03No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 6 non-independent directors. Member of Advisory Board Andrew Samann was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • Nov 16No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 6 non-independent directors. Member of Advisory Board Andrew Samann was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Nov 10Nirvana Life Sciences Inc. Appoints Sheldon Inwentash to the Company's Board of DirectorsNirvana Life Sciences Inc. announce the appointment of Mr. Sheldon Inwentash to the Company's Board of Directors. Mr. Inwentash is founder, chairman and chief executive officer of ThreeD Capital Inc. A veteran entrepreneur, Sheldon has more than 30 years of successful investing experience and an extensive track record of achieving significant ROI for his investors and profitability for the companies in which he invests. He founded ThreeD Capital to provide unique investment opportunities in several areas, specifically early stages of small cap stock, resource and disruptive technologies. Sheldon graduated from the University of Toronto with a B.Comm degree and, later, was awarded an honorary Doctor of Law degree from the university for his leadership as an entrepreneur, philanthropist and for his dedication to youth.
お知らせ • Sep 08Nirvana Life Sciences Inc. Announces Method for Producing MDMA That Reduces Manufacturing Time by Two ThirdsNirvana Life Sciences Inc. report the development of a more efficient method for producing MDMA. Nirvana Life Sciences Inc. announced the development of a novel method of producing MDMA (3,4-methylenedioxy methamphetamine) that greatly reduces manufacturing time. This 3-step synthesis, starting from the precursor safrole, takes as little as 24 hours to complete, depending upon which method of reduction of the ketone to the secondary amine is being used. This is approximately one third of the time that's required to complete current production methods using iso-safrole as an intermediate. Nirvana has filed an Application with the US Patent Office for this invention. MDMA was first synthesized in 1912, but it was not researched for its therapeutic potential until just recently. The drug is a potent central nervous system (CNS) stimulant the varies greatly in effect from other common stimulants found in the same phenethylamine family of compounds. It is currently being studied and used for the treatment of a wide range of psychiatric disorders such as Post Traumatic Stress Disorder (PTSD), depression and anxiety to name a few. MDMA assisted psychotherapy is currently in phase three clinical trials for the treatment of PTSD in the US, Canada, and Israel. This year the FDA expanded access to MDMA, allowing for its compassionate use in clinical settings by patients who have had no success with other FDA approved treatment options. MDMA effectively shuts down the brain's fight-or-flight response and creates a sense of empathy in patients, allowing them to process trauma more effectively. The drug increases the amount of serotonin in the synaptic clefts of serotonergic neurons. It also binds to various serotonin receptors and activates them in excess, while simultaneously reducing the reuptake of other neurotransmitters, which is the drugs primary mechanism of action Lead chemist and Head of Innovation for Nirvana Life Sciences Inc., Robert August, was one of the first researchers to successfully crystallize MDMA HCl Monohydrate, a novel form of MDMA with increased bioavailability and efficacy. The method of synthesis that he developed can also be seamlessly integrated into the production of MDMA HCl Monohydrate, of which Nirvana Life Sciences Inc. recently announced a patent pending for. With the growing surge in interest in the research of MDMA in the past few years, and the increasing potentials of its use in therapeutic settings, Nirvana believes that this breakthrough is a significant advance in the emerging psychedelic medicines space.
お知らせ • Aug 09Nirvana Life Sciences Inc. Announces Executive ChangesNirvana Life Sciences Inc. announced that Connie Hang has resigned as Chief Financial Officer of the Company. She will continue serving the Company as a Contractor. Annie Storey, CPA, CA, BBA has been appointed as Chief Financial Officer, effective immediately. Ms. Storey, a director of the Company since 2017, brings over 25 years' experience in accounting, auditing, financial reporting and corporate services for Canadian and US public companies in the mining, entertainment and biotechnology sectors. Ms Storey has a keen interest in the development new approaches to manage addictions and currently serves as a director of the advocacy group Moms Stop the Harm.
お知らせ • Jun 24Nirvana Life Sciences Announces Filing of Patent for Novel Isolation of 4-PO-Psilocin Prodrug CompoundNirvana Life Sciences Inc. reported that it has filed a provisional patent application for a novel process for the isolation of a psychedelic 4-PO-Psilocin compound. The process, developed by Nirvana's Head of Innovation, Robert August allows for the isolation of 4- PO-Psilocin, a substituted tryptamine and psychoactive prodrug that is produced alongside psilocybin and psilocin. Its pharmacological effects are virtually identical to those produced by psilocybin since both are prodrugs. Both are metabolized in the human body to produce the psychoactive compound psilocin, which is responsible for the majority of psychoactive effects. The 4-PO-Psilocin can be purified by crystallization to an API. It can also be converted to a biologically active and water-soluble salt to yield a final compound 4-PO-Psilocin with a purity greater than 99%. The ability to convert the 4-PO-Psilocin compound into a water-soluble salt will change the current landscape of delivery systems in the psychedelic sector. The high rate of bioavailability will lower the required volume of psychedelic compound to achieve the same result. This will substantially increase the efficacy and safety in administering psychedelic compounds in clinical settings.
お知らせ • Jun 11Nirvana Life Sciences Announces Patent FilingNirvana Life Sciences Inc. report that it has filed a new provisional patent application with the United States Patent and Trademark Office entitled Method of Psilocybin Extraction and Method of use of Psilocybin in modulating Heroin and Memory Retrieval (the "Patent Application"). The Patent Application contains new inventive claims for extraction as well as inventive methods for use of Psilocybin to affect relapse and further demonstrates the progress that the Company is making toward developing products that can have a meaningful impact on opioid addiction.
お知らせ • Jun 04Nirvana Life Sciences Inc. Announces Positive Results for Addiction Relapse Prevention from Their Latest Pre-Clinical Psychedelic Drug StudyNirvana Life Sciences Inc. in conjunction with Integrative Therapy Discovery Labs in Italy, have released comprehensive data on a scientific study that aims in determining the effects that psilocybin has on the heroin addicted brain. The study was carried out by Dr. Massimo Nabissi, from the School of Pharmacy Section of Experimental Medicine, University of Camerino in Camerino, Italy. The preclinical study evaluated the effect of psilocybin on in-vitro rat brain cell line models and an in-vivo rat model on heroin self-administration and reinstatement of heroin seeking behavior following memory retrieval tests. Drug self-administration is regarded as a gold-standard preclinical model of addiction and substance-use disorders. The aim of the project was threefold and are as follows. To evaluate the effect of psilocybin in modulating heroin molecular pathways in vitro rat brain cell line models. To evaluate the effect of psilocybin on heroin self-administration. To evaluate the effect of psilocybin on reinstatement of heroin seeking following memory retrieval test. Gene Analysis was performed by the Clariom S Assay tool. This machine serves as a next generation transcriptome-wide gene-level expression profiling tool, which allows for the fastest, simplest, and most scalable path to generating actionable results. Based on industry-leading microarray technology, the novel rat Clariom S Assay provides extensive coverage of all known well-annotated genes, compatibility with clinical sample types, scalable formats, and flexible data analysis software. The GeneChip Rat Genome 230 2.0 Assay was used to evaluate gene expression levels and in cell lines that were treated with heroin and psilocybin and with psilocybin in combination with heroin. The immortalized rat hypothalamus cells were derived from the hypothalamus of a 4-month-old Fisher Rat. The hippocampal cells derived from the rats' hippocampi were treated daily with heroin and psilocybin, alone or in combination. After 48 hours, cell lines were collected for RNA extraction and gene array analysis. For each of the comparisons indicated, an electronic file was created that includes differentially expressed transcripts that were identified in both H19-7 and RCTH-1 cells with extended annotations. A second file was created that made comparisons evidencing only the transcript differences where the Ct value was highly different as a final analysis. For each of these data sets, only the genes whose expression was reverted by psilocybin and in the treatments consisting of heroin plus psilocybin were selected. Moreover, only the genes whose expression was psilocybin dose dependent were considered. In summary, the potential candidate genes whose expression in heroin treatment was reverted by psilocybin and evidenced in the electronic file reports were selected. The effect of heroin and psilocybin in reducing cell viability was evaluated in HT19-7 and RCHT-1 cell lines by daily administration. Cells were treated for 48 hours with either heroin or psilocybin or with a combination of heroin with psilocybin and then were analyzed. The percentage of cell viability was evaluated by a cell viability assay whose results showed a dose-dependent heroin effect in the RCHT-1 cell line with specific IC50 values. While in HT19-7 cell lines, no cytotoxic effects were observed at the concentrations used. Regarding psilocybin, similar results were obtained in cell lines with specific IC50 values and with both RCHT-1 and HT19-7 cell lines. To gain further insight, heroin was combined with psilocybin at varying doses to evaluate the optimal combination for transcriptional study. The results showed that when used together at varying dosages, the combinations were not cytotoxic in either of the two cell lines. The study goes on to show how treatment with psilocybin effected self-administered heroin use via lever presses along with the overall effect that psilocybin combined with heroin had on certain behavioral models in both male and female Wistar rat populations. A preliminary experiment aimed at testing the efficacy of psilocybin to prevent heroin relapse following cue memory reconsolidation was also conducted. Altogether, these results suggest that psilocybin decreased reinstatement of heroin seeking in female rats. As a final analysis, the gene data evidenced in the study was subjected to a comprehensive academic wide search of available current littérature and, although information regarding a correlation with psilocybin and opioid addiction was available, a transcriptome analysis for heroin and psilocybin and their co-combination has never been previously investigated. As a result, the data presented in this study can be extremely useful for determining a better understanding of dependent doses and the molecular mechanisms involved in the potential modulation of heroin (or opioids in general) addiction and dependence. In summary, the information contained within the study dealing with relapse prevention is new and groundbreaking evidence in the field of pharmaceutical addictions medicine and chemotherapy. This type of comprehensive study, which constitutes concrete scientific evidence-based data, is at the heart of Nirvana Life Sciences' business objective which is to develop and seek FDA approval for therapeutic formulations and novel pharmaceuticals.
お知らせ • Jun 01Nirvana Life Sciences Inc. announced that it has received CAD 0.15 million in funding from ThreeD Capital Inc.Nirvana Life Sciences Inc. (CNSX:NIRV) announced a non-brokered private placement of 500,000 units at a price of CAD 0.30 per unit for gross proceeds of CAD 150,000 from returning investor ThreeD Capital Inc. on May 31, 2022. Each unit consists of one share and one warrant to purchase a share at a price of CAD 0.50 per share with an expiry date of May 29, 2025. The shares issued will be subject to a statutory four-month hold period.
Board Change • Apr 27No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Member of Advisory Board Andrew Samann was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Apr 06Nirvana Life Sciences Inc. Announces the Appointment of Andrew Samann to Advisory BoardNirvana Life Sciences Inc. announced the appointment of Mr. Andrew Samann to the Company's Advisory Board. Andrew Samann is CEO and Principal Consultant of Orion GMP Solutions.